Danish Biotech Samplix Secures €25 Million First Close to Scale Single-Cell Platform
Danish biotech Samplix announced a €25 million first close of its financing round, led by WLanholding GmbH. The funds will be used to scale the Xdrop droplet microfluidics platform for antibody discovery and to explore AI‑driven drug discovery. The round includes €3 million in new equity and €22 million in convertible bonds, with a total target of €30 million. Dr. Werner Lanthaler of WLan will join Samplix’s board, supporting the company’s next growth phase.